TScan Therapeutics (TCRX) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

TCRX TScan Therapeutics

Watchlist

2.940
+0.040+1.38%

Trading Dec 19 10:22 ET

156.91MMarket Cap-3.09P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Purchase: 10% Owner at $TCRX (TCRX) Buys 31,800 Shares
Quiver QuantitativeDec 16 16:32 ET
A Quick Look at Today's Ratings for TScan Therapeutics(TCRX.US), With a Forecast Between $11 to $15
Moomoo NewsDec 12 08:00 ET · Ratings
TScan Therapeutics: Promising Phase I ALLOHA Trial Results and Future Pivotal Study Drive Buy Rating
TipRanksDec 12 05:26 ET · Ratings
TScan Therapeutics (TCRX) Gets a Buy From Barclays
TipRanksDec 12 04:15 ET · Ratings
The Analyst Landscape: 5 Takes On TScan Therapeutics
BenzingaDec 11 09:01 ET
TScan Therapeutics Price Target Maintained With a $11.00/Share by Needham
Dow JonesDec 11 08:24 ET · Ratings

Comments

Trytosaveabit

Dec 9 16:55

Watching

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics To Present Updated Results From Ongoing ALLOHA Phase 1 Trial Of TSC-100 And TSC-101 At ASH Meeting
Benzinga· 1 min ago
TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning.
The company said it is high...

MARKET-TEST-DUMMY

Dec 7 05:06

👁

$TScan Therapeutics (TCRX.US)$

Jaguar8

Nov 5 08:16

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Jaguar8

Oct 4 10:40

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...

Trytosaveabit

May 29 06:08

News

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Says FDA Granted Regenerative Medicine Advanced Therapy Designation To TSC-100 And TSC-101
Benzinga· 2 mins ago

Heat List

Overall

No Data